* Respiratory sales growth in Emerging Markets of 18% (26% at CER) to $518m, driven by the aforementioned sales growth of Pulmicort
number]   *     #  Breezhaler 0.02 0.0197 0.019 0.017 (Neohaler) Clickhaler 0.0394 Diskhaler 0.032 Diskus 0.0275 0.0249 0.034 0.026 0.027 (Accuhaler) Ellipta 0.0275 0.027 Easyhaler 0.0424 0.037 0.050 Genuair 0.031 [0.028] 0.029 0.031 (Pressair) [Novoliser] HandiHaler 0.0510 0.05 0.058 Nexthaler 0.036 0.042 0.033 0.036 Spiromax 0.0313 (Respiclick) Turbuhaler 0.0382 0.0337 0.043 0.039 0.039 Pulmicort
Turbuhaler 0.0355 0.033 0.035 Symbicort (Flexhaler) Twisthaler 0.044 Note.
, a corticosteroid, is a long-term medication that attacks asthma by reducing swelling in the tiny passages in the lungs that can become irritated and thick with mucous.
AstraZeneca also announced that a US federal appeals court had issued a temporary injunction blocking generic manufacturers from distributing versions of Pulmicort
Respules, an asthma treatment.
In the main market, pharmaceutical giant AstraZeneca announced that the United States District Court has ruled that the group's patent protecting its asthma drug, Pulmicort
Respules, is invalid in the US.
Another claim by certain pharmaceutical companies is that some patients are receiving "generic budesonide" instead of Pulmicort
Respules[TM] for their inhalation treatments.
SkyePharma PLC (LSE: SKP), a producer of proprietary drug delivery technologies, has been advised by AstraZeneca (LSE: AZN), an integrated biopharmaceutical company, that production of SKP's PULMICORT
(budesonide) 100 and 200 -microg/dose HFA pMDI (pressurised metered dose inhaler) is to be discontinued.
Generic competition for Pulmicort
Respules for asthma and Toprol-XL blood-pressure treatment also hurt sales.
Swimming Australia (SA) said Napoleon, 20, has taken the asthma medication Pulmicort
for most of his life.
The current phase II study, sponsored by Meritage Pharma Inc., the maker of OVB, is the first placebo-controlled study to evaluate the drug, which is a viscous liquid consisting of budesonide nebulizer suspension (Pulmicort
respules) mixed with sucralose (Splenda).
The Anglo-Swedish pharma major will pay USD13m to two classes of plaintiffs -- third-party payers who paid some or all of their Medicare co-insurance for its cancer drug Zoladex and/or its asthma treatment Pulmicort
Respules in the northeastern US state of Massachusetts as well as consumers and third-party payers who paid cash or a co-pay for these drugs outside of Medicare in Massachusetts.
and Apotex Corp.) from launching a generic version of AstraZeneca's PULMICORT
RESPULES (budesonide inhalation suspension) in the US.